Factor 8 Hemlibra denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Hemlibra as Duplicate Therapy — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is a subcutaneous bispecific antibody that bridges activated factor IX and factor X, mimicking the cofactor function of factor VIII. Aetna may issue a duplicate-therapy denial when a patient is also prescribed a traditional factor VIII concentrate or bypass agent, reasoning that both therapies serve the same prophylactic or treatment purpose. However, Hemlibra's mechanism is fundamentally distinct from factor VIII concentrates — it does not replace factor VIII, and clinical use of both agents concurrently may be intentional and medically necessary (for example, during surgical procedures or breakthrough bleeds while on Hemlibra prophylaxis).

## Why This Denial Is Appealable

A duplicate-therapy determination requires Aetna to show that both agents are clinically interchangeable or that concurrent use is without medical rationale. Given Hemlibra's unique mechanism and the documented need for supplemental factor products in certain scenarios, this characterization is frequently incorrect. The treating hematologist is the appropriate authority to explain why concurrent use — or transition use — is clinically necessary.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; file within 180 days of the denial.
• ACA §2719 (fully-insured plans): Independent external review after exhausting internal appeals, generally within four months of final internal denial.
• Expedited review: Available when standard timelines would jeopardize health or function; typically resolved within 72 hours at both the internal and external stages.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter confirming the duplicate-therapy rationale. 2. Request Aetna's written coverage policy for Hemlibra and any policy defining what constitutes duplicate therapy. 3. Prepare a clinical narrative explaining the distinct mechanism and the specific reason for concurrent or transitional use. 4. File the internal appeal with supporting documentation within the stated deadline. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis documentation: Confirmed hemophilia A diagnosis with inhibitor status clearly stated.
• Medication list with clinical rationale: Each agent being prescribed, its intended purpose, and why the purposes are not duplicative.
• Prescriber letter: The hematologist should explain Hemlibra's mechanism, why it does not replace the concurrent agent, and the clinical scenario requiring both.
• Treatment history: Prior prophylaxis or treatment regimens, bleed events, and outcomes.

## Criteria-Mapping Structure

Obtain Aetna's published coverage policy for Hemlibra and its duplicate-therapy definition. For each criterion, map the chart evidence that demonstrates the therapies serve distinct clinical functions for this patient. A clear pharmacological explanation of the difference between emicizumab and factor VIII concentrates — written by the treating hematologist — is typically the pivotal document in this type of appeal.